Covariate | Hazard ratio (95 % confidence interval) | |
---|---|---|
Model for interval censored data [24] | Gap-time Cox model [2] | |
Magnitude of first blip (reference no blips) | ||
Low (50–199 copies/mL) | 1.20 (0.89, 1.61) | 1.03 (0.77, 1.38) |
Medium (200–499 copies/mL) | 1.42 (0.96, 2.19) | 1.25 (0.86, 1.82) |
High (500–999 copies/mL) | 1.93 (1.24, 3.01) | 1.69 (1.10, 2.60) |
Female | 1.16 (1.03, 1.30) | 1.12 (1.00, 1.25) |
Injection drug usea | 1.21 (1.04, 1.41) | 1.25 (1.08, 1.45) |
Age (per 10 years) | 0.91 (0.86, 0.97) | 0.89 (0.84, 0.95) |
Calendar year episode began (per year) | 0.92 (0.90, 0.94) | 0.93 (0.91, 0.95) |
Assay (reference Roche Amplicor ultrasensitive) | ||
Abbot RealTime | 2.19 (0.65, 7.41) | 2.46 (0.81, 7.47) |
Roche TaqMan version 1 | 0.90 (0.65, 1.25) | 0.87 (0.63, 1.19) |
Roche TaqMan version 2 | 1.31 (0.93, 1.86) | 1.23 (0.88, 1.72) |
cART regimen (reference NNRTI based) | ||
Boosted PI | 1.85 (1.62, 2.10) | 1.76 (1.55, 2.01) |
Single PIb | 1.73 (1.39, 2.16) | 1.68 (1.35, 2.09 |
Entry or integrase inhibitorc | 1.98 (1.63, 2.41) | 1.77 (1.45, 2.15) |
Noned | 10.6 (8.17, 13.7) | 8.70 (6.87, 11.0) |
CD4 cell count (per 100 cells/μL)e | ||
0 to <200 | 0.74 (0.57, 0.97) | na |
≥ 200 | 1.01 (0.98, 1.03) | na |
RNA tests per year (reference >6)e | ||
≤ 3 | na | 0.31 (0.23, 0.42) |
3- ≤ 4 | na | 0.36 (0.27, 0.48) |
4- ≤ 6 | na | 0.47 (0.27, 0.48) |